Protein Ingredient Market Size & Share 2026-2035

Global Protein Ingredients Market Size

The global protein ingredients market was valued at USD 52.8 billion in 2025 and is estimated to reach USD 56.7 billion in 2026 and USD 112.9 billion by 2035, expanding at a CAGR of approximately 7.9% from 2026 to 2035. Volume is projected to increase from 11,976 KT in 2025 to 12,878 KT in 2026 and 25,691 KT in 2035, representing a CAGR of approximately 7.98%. Value growth therefore depends on both rising consumption and a shift toward higher-functionality formats, including isolates and hydrolysates.

Protein ingredients include animal-derived, plant-derived, and alternative sources processed into concentrates, isolates, hydrolysates, and textured proteins. Their role is expanding beyond traditional sports powders. Mainstream foods, clinical nutrition, meal replacements, infant nutrition, beauty supplements, and animal feed increasingly require proteins with specified solubility, sensory, digestibility, or bioactive characteristics. Global dietary protein supply increased from roughly 85 g per person per day in 2010 to more than 90 g in 2021, although regional availability and dietary patterns remain uneven ^[1]. Longer-term nutrition scenarios continue to identify protein adequacy and supply diversification as important food-system issues ^[2].

Consumer demand is supplying the immediate pull. Cargill reported that 61% of U.S. consumers increased protein intake in 2024, compared with 48% in 2019, while 57% of label readers examine protein content ^[3]. The International Food Information Council found that 71% of Americans were actively trying to increase protein intake in 2024 ^[4]. These signals matter because they move protein from a specialist nutrition claim into an everyday formulation requirement for snacks, beverages, dairy products, and convenience foods.

The alternative-protein opportunity remains uneven. Continuous fermentation has demonstrated more than threefold productivity gains and a 50% cost reduction at a 3,000-liter scale ^[7], but that progress does not erase the cost and consumer-acceptance barriers facing insect and cultivated proteins. Conventional dairy, soy, pea, and collagen suppliers are therefore positioned to capture nearer-term demand, while fermentation platforms must demonstrate repeatable economics and regulatory fit in premium applications before they materially alter source-market shares.

Report Coverage & Key Takeaways

Key Drivers

Protein is becoming a formulation requirement in mainstream food. Health, satiety, weight management, and active-aging needs are broadening the customer base for protein-fortified products. ADM found that 70% of Millennials and Generation Z consumers seek more protein, compared with 58% of Baby Boomers ^[5]. Among consumers using GLP-1 medications, 64% report paying more attention to protein and 44% are intentionally increasing plant-based protein consumption. Smaller portions with higher nutrient density create particular demand for isolates and hydrolysates, which allow manufacturers to raise protein content without proportionally increasing serving size.

Sports and clinical nutrition support higher-value protein formats. The commercial opportunity is not limited to retail powders. Fonterra is investing approximately AUUSD 75 million in functional-protein capacity at Studholme for medical and sports nutrition applications ^[9]. Glanbia Nutritionals reported USD 200 million in 2024 EBITDA for Nutritional Solutions, up 27.2% in constant currency, with a 19.8% margin. Those economics show why processors are prioritizing specialized whey, peptide, and blended-protein systems instead of competing only in bulk concentrate markets.

Plant proteins are diversifying beyond meat analogs. U.S. plant-based meat sales declined in 2025, but plant-based bars grew 16% in dollar sales, and plant-based milk generated USD 2.7 billion in sales, accounting for 13% of total milk dollar sales ^[6]. This divergence matters for ingredient suppliers: beverage, bar, dairy-alternative, and nutritional applications reward better flavor, solubility, and allergen-management performance, whereas textured-protein demand remains more exposed to meat-alternative category volatility. Ingredion and Lantmännen's planned Swedish pea-protein facility, supported by more than €100 million of investment, is expected to be completed in 2027 ^[8].

Key Restraints

Alternative-protein economics remain difficult to scale. Insect meal costs roughly 10 times as much per tonne as soybean meal and 3.5 times as much as fishmeal, according to a 2026 assessment of insect farming economics ^[10]. The resulting gap limits adoption in feed and food formulations where protein is purchased against established commodity benchmarks. Ÿnsect ceased operations in December 2025 after raising more than €600 million, while Innovafeed suspended operations at its Decatur facility. These outcomes demonstrate that funding and pilot capacity do not independently establish viable unit economics.

Precision fermentation has a more credible route in products where protein functionality, purity, or animal-free positioning can command a premium. Yet it still requires capital-intensive bioreactors, energy, feedstock, and downstream purification. Cultivated protein faces an additional engineering burden in cell-media cost, contamination control, and waste separation at scale. Cost reductions demonstrated in fermentation are significant, but their commercial relevance depends on whether they can be replicated across continuous, food-grade production systems.

Acceptance and regulation slow adoption of unfamiliar sources. Consumer hesitation toward insects remains a separate restraint from production cost. The SUSINCHAIN consortium identified social acceptance alongside finance, regulation, safety, and price as a co-equal barrier to scaling insect proteins in Europe. Novel-food applicants also face lengthy information requests and assessment timelines under the European Food Safety Authority framework. In March 2026, the European Union agreed to restrict use of "meat" and 31 related terms for fermentation-enabled, plant-based, and cultivated products, tightening the marketing constraints on categories already seeking familiar consumer language.

The projected alternative-proteins CAGR of approximately 7.35% therefore represents selective commercialization rather than broad substitution. Suppliers and investors should distinguish between platforms capable of selling into premium nutrition or specialty formulations and technologies that still depend on consumers accepting a novel protein source at a material price premium.

Global Protein Ingredients Market Segment Analysis

By Source

Animal-derived proteins are projected to increase from USD 29.51 billion in 2025 to USD 62.86 billion by 2035, at approximately 7.90% CAGR. Dairy proteins retain an advantage in sports, clinical, and infant nutrition because whey and casein have established functionality and regulatory familiarity. The strategic issue is not simply dairy supply; it is the ability to convert dairy co-products into high-margin isolates, hydrolysates, and specialized blends. Fonterra's specialty-protein investment and Glanbia's Nutritional Solutions profitability illustrate this movement toward value-added formats.

Collagen and gelatin add a circular-economy dimension to animal-derived proteins. Darling Ingredients estimates that it produces approximately 30% of global collagen output through a network of more than 260 facilities in over 15 countries. Its access to rendering and by-product streams creates a supply advantage in collagen peptides, gelatin, and specialty animal proteins used across food, supplements, pharmaceuticals, and personal care. Egg proteins remain important where foaming, emulsification, and specialized peptide functionality are difficult to reproduce economically with plant alternatives.

Plant-derived proteins are estimated to grow from USD 20.24 billion in 2025 to USD 43.90 billion in 2035, at approximately 8.10% CAGR. Soy retains the deepest processing infrastructure, but pea, fava, wheat, and blended proteins are gaining relevance where manufacturers require non-GMO, allergen-managed, or regionally sourced formulations. Roquette launched NUTRALYS® Fava S900M, a 90% protein fava isolate, in May 2024. Its later textured wheat and pea products broadened the toolkit available to hybrid and plant-forward food developers.

Wheat proteins maintain a distinct role in bakery and texturization. CropEnergies' Wanze facility produces more than 60,000 tonnes of wheat gluten annually, linking protein production to a biorefinery co-product model. That integration can improve raw-material utilization and offers European manufacturers an in-region option for bakery fortification and meat-alternative texturization. The segment's growth will depend on sensory improvement and application fit, rather than on plant-based positioning alone.

Alternative proteins are projected to rise from USD 3.01 billion in 2025 to USD 6.09 billion by 2035, at approximately 7.35% CAGR. Precision fermentation is the most commercially established pathway within this group because it can produce specific proteins with familiar end-use functionality. The Good Food Institute identified more than 163 companies and research institutions active in fermentation-derived proteins, with USD 357 million raised by the sector in 2025. South Korea's Food Tech Industry Promotion Act and Chinese biotechnology policy support for precision-fermented dairy and egg proteins may improve the Asia Pacific commercialization environment.

By Type

Protein concentrates are estimated to increase from USD 22.13 billion in 2025 to USD 47.18 billion in 2035, at approximately 7.91% CAGR. Their lower processing intensity makes them appropriate for high-volume applications, including bakery, dairy, feed, and value-oriented fortified foods. Concentrates remain essential to market volume, but their pricing is more exposed to raw-material availability and commodity protein cycles.

Protein isolates are projected to grow from USD 17.46 billion in 2025 to USD 37.70 billion by 2035, at approximately 8.05% CAGR. Their high purity and improved solubility make isolates appropriate for clear beverages, premium powders, dairy alternatives, and clinical formulations. Capacity investments in pea protein are particularly relevant because manufacturers increasingly require plant proteins that can meet sensory and dispersibility specifications formerly associated with dairy ingredients.

Protein hydrolysates are forecast to rise from USD 9.03 billion in 2025 to USD 19.75 billion by 2035, at approximately 8.18% CAGR. Enzymatic hydrolysis can improve digestibility, reduce allergenicity, and create bioactive peptide fractions. Kerry's protein-hydrolysate platform addresses performance and clinical nutrition applications, while Kewpie's EGG WHITE PEPTIDES EP-1 combines a low average molecular weight of approximately 1,100 Da with ACE-inhibitory and antioxidant properties. These attributes support use cases where protein is expected to deliver a defined physiological or formulation benefit.

Textured proteins are estimated to increase from USD 4.14 billion in 2025 to USD 8.24 billion by 2035, at approximately 7.17% CAGR. Demand remains closely tied to meat-alternative and hybrid-product innovation. Extruded soy, pea, and wheat proteins provide structure and bite, but slower retail performance in some plant-based meat categories makes this type more cyclical than isolates or hydrolysates. New textured wheat and pea formats from Roquette reflect ongoing formulation work, although category growth will require products that satisfy taste, price, and convenience expectations.

By Application

Food applications are projected to increase from USD 33.35 billion in 2025 to USD 71.78 billion by 2035, at approximately 8.01% CAGR. Beverages, protein bars, dairy alternatives, bakery products, and hybrid foods are broadening demand beyond conventional supplements. Product developers must manage viscosity, flavor, sedimentation, and processing stability; consequently, application-ready protein systems often command more value than undifferentiated protein flour or concentrate.

Nutritional applications are estimated to grow from USD 14.80 billion in 2025 to USD 31.83 billion by 2035, at approximately 8.00% CAGR. Sports nutrition, clinical nutrition, infant nutrition, dietary supplements, and meal replacements create demand for digestibility, amino-acid quality, and allergen management. This application group is commercially important because it converts functional performance into pricing power. Protein suppliers with taste masking, hydrolysis, blending, and clinical-formulation capabilities are better positioned than suppliers limited to raw protein output.

Non-food applications are forecast to increase from USD 4.61 billion in 2025 to USD 9.25 billion by 2035, at approximately 7.26% CAGR. Collagen peptides, gelatin, keratin, and specialty protein fractions serve personal care, pharmaceutical, and feed uses. This category offers a channel for by-product valorization, but qualification standards and end-use-specific documentation can limit substitutability between suppliers.

Plant proteins are also becoming less dependent on a single meat-alternative demand cycle. Bars, beverages, dairy alternatives, and GLP-1-oriented nutrition products can absorb isolates and specialty ingredients even when textured-protein demand is softer. That diversification lowers reliance on one category, but it raises the technical threshold for plant-protein suppliers because sensory performance and formulation support become central purchasing criteria.

Global Protein Ingredients Market Regional Analysis

North America is projected to grow from USD 14.26 billion in 2025 to USD 30.59 billion by 2035, at approximately 7.98% CAGR. High consumer attention to protein, mature sports-nutrition channels, and established soy and dairy processing support demand. Bunge's approximately USD 550 million Morristown, Indiana, facility began expanding U.S. capacity for soy protein concentrate and textured soy protein in 2025. North America also has an early regulatory lead in precision-fermented dairy proteins following FDA GRAS determinations, supporting first commercial use in selected food applications.

Europe is estimated to increase from USD 13.18 billion in 2025 to USD 28.10 billion by 2035, at approximately 7.91% CAGR. The region combines strong functional-food demand with high regulatory and sustainability requirements. The European Commission authorized duckweed protein concentrate from *Lemna gibba* and *Lemna minor* as a novel food in April 2024. However, novel-food approvals can require extended technical engagement with EFSA, which favors suppliers able to fund regulatory dossiers and maintain evidence packages. Regional wheat and pea processing investments also support traceability and local-sourcing strategies.

Asia Pacific is the largest regional market, estimated at USD 18.99 billion in 2025 and projected to reach USD 41.08 billion by 2035, at approximately 8.07% CAGR. China provides scale across soy processing, dairy ingredients, and urban nutrition products. India creates demand for plant proteins through its large vegetarian consumer base and a widening urban market for fortified foods and sports nutrition. Japan's specialty nutrition demand supports collagen peptides and bioactive proteins, while South Korea's Food Tech Industry Promotion Act creates a supportive policy setting for fermentation-enabled foods. The regional opportunity is therefore diversified across commodity, premium, clinical, and emerging-technology formats.

Latin America is projected to grow from USD 4.20 billion in 2025 to USD 8.80 billion by 2035, at approximately 7.74% CAGR. Brazil's soybean complex provides a substantial raw-material and processing base, while regional consumption is gradually shifting toward protein-fortified packaged foods, supplements, and convenience products. The principal competitive advantage remains cost-efficient agricultural supply; the principal constraint is that specialty isolates and hydrolysates often require greater processing capability and customer-development investment than bulk soy products.

Middle East & Africa is forecast to increase from USD 2.14 billion in 2025 to USD 4.29 billion by 2035, at approximately 7.22% CAGR. The region's smaller scale reflects greater import dependence for specialty proteins and a less mature functional-food manufacturing base. However, food-security investment, modern retail expansion, and halal qualification requirements create targeted opportunities for pea, soy, dairy, and marine-derived proteins. Suppliers able to document source, processing, and halal compatibility can reduce procurement friction in markets where qualification is as important as nutrient specification.

North America remains strategically important for innovation and commercialization, particularly in premium nutrition and precision fermentation, while Europe provides a large but regulation-intensive market for traceable plant and novel proteins. Suppliers should avoid treating regional expansion as a simple distribution decision. Regulatory pathways, local raw-material economics, sensory preferences, and certification needs materially change which protein source and processing format can succeed in each market.

Global Protein Ingredients Market Share & Competitive Landscape

Competition is structured around access to raw materials, processing technology, application knowledge, and regulatory capability. Diversified agricultural processors compete through scale and supply-chain integration, while specialists differentiate through hydrolysis, fermentation, texture, sensory systems, collagen processing, or a focused protein-source portfolio. The market's breadth prevents a single capability from determining leadership across all applications.

Archer Daniels Midland operates more than 330 food and feed ingredient manufacturing facilities and 62 innovation centers. Its scale across agricultural processing and nutrition ingredients supports plant-protein development, while targeted cost savings of USD 500 million to USD 750 million demonstrate the importance of operating efficiency in an environment where commodity and specialty protein economics coexist.

Cargill, Incorporated combines raw-material procurement, processing, and application work across animal, plant, and specialty protein systems. Its consumer research shows how protein demand is moving toward convenience, satiety, health, and taste rather than remaining tied to muscle building alone. That breadth positions Cargill to translate consumer behavior into formulation opportunities across food and nutrition customers.

CropEnergies AG uses its European biorefinery model to produce wheat gluten and textured wheat protein alongside ethanol operations. More than 60,000 tonnes of annual wheat-gluten output at Wanze supports regional supply for bakery and texturized-food applications. The December 2024 decision to pause the EnPro® investment in the United Kingdom also illustrates the effect of capital costs and market conditions on protein co-product expansion.

Darling Ingredients processes animal by-products into collagen, gelatin, blood plasma, and specialty proteins. With net sales of USD 5.715 billion in 2024, its circular processing model provides a differentiated feedstock position in collagen and animal-derived ingredient markets. The company's advantage rests on converting complex by-product streams into qualified ingredients for food, supplements, personal care, and pharmaceuticals.

Fonterra Co-operative Group reported FY25 revenue of NZUSD 26 billion and is sharpening its B2B ingredient focus. Its Studholme expansion targets functional proteins for sports and medical nutrition, aligning dairy supply with higher-value end uses. The agreement to sell its global Consumer businesses to Lactalis for NZUSD 4.22 billion further emphasizes portfolio concentration on ingredient and foodservice operations.

Glanbia Nutritionals is concentrated in performance, functional, and clinical nutrition. Nutritional Solutions generated USD 200 million in 2024 EBITDA with a 19.8% margin. Its acquisition of Flavor Producers strengthens a critical complement to protein formulation: taste management. This capability is commercially relevant because higher inclusion rates can intensify off-notes and texture challenges in protein-enriched products.

Ingredion Incorporated is expanding its European pea-protein position through its partnership with Lantmännen. The planned Swedish facility combines regional yellow-pea supply with Ingredion's application and commercial capabilities. This structure can improve traceability and reduce dependence on imported plant-protein inputs for European customers.

International Flavors & Fragrances reported 2024 net sales of USD 11.484 billion. Its SUPRO® and SUPRO® TEX protein portfolio supports soy-based fortification and texturization, while its agreement to sell certain soy concentrate, lecithin, and crush operations to Bunge allows the company to focus more closely on higher-margin isolate activities.

Kerry Group reported 3.4% volume growth in FY2024 for its Taste & Nutrition business. Its protein-hydrolysate capabilities serve performance, clinical, and functional-nutrition customers where peptide profile and sensory performance can be decisive. The divestment of Kerry Dairy Ireland in December 2024 reinforces its shift toward specialty taste and nutrition systems.

Kewpie Corporation supplies specialty egg-derived proteins through its fine-chemicals operations. EGG WHITE PEPTIDES EP-1 uses enzymatic hydrolysis to achieve an average molecular weight of approximately 1,100 Da and provides branched-chain amino acids with ACE-inhibitory and antioxidant properties. Its specialization illustrates how egg proteins can move from functional food ingredients into bioactive nutrition applications.

MGP Ingredients, Inc. supplies wheat proteins and textured plant proteins for bakery, egg replacement, meat alternatives, and specialty food applications. Its Ingredient Solutions sales rose 4% to USD 34.7 million in the fourth quarter of 2024. The company's wheat-protein position is differentiated by its role in structure, dough performance, and clean-label formulation rather than protein fortification alone.

Perfect Day, Inc. produces dairy proteins through precision fermentation. The FDA's March 2020 GRAS notice for beta-lactoglobulin produced using *Trichoderma reesei* established a U.S. regulatory foundation for the company's protein platform. Its strategic importance lies in demonstrating that bioidentical dairy proteins can enter food systems through a non-animal production pathway, subject to competitive manufacturing economics.

Roquette Frères continues to broaden its NUTRALYS® portfolio across fava, pea, wheat, and textured proteins. Its 2024 fava isolate launch, 2025 textured wheat and pea launches, and February 2026 Pea 850F launch show a strategy centered on diversified source options and targeted application performance. The Pea 850F launch responded to a 29% increase in food and beverage launches carrying protein and weight-management claims during 2024-2025.

Recent Industry Developments

Bunge expanded U.S. soy-protein capacity in 2025. Bunge invested approximately USD 550 million in a Morristown, Indiana, soy-processing facility designed to produce soy protein concentrate and textured soy protein concentrate. The project adds domestic capacity at a time when food manufacturers are seeking greater supply security for plant-protein ingredients.

FrieslandCampina acquired Wisconsin Whey Protein in December 2025. The acquisition expanded FrieslandCampina Ingredients' North American presence and global whey protein isolate capacity. The transaction reflects continued consolidation around premium dairy-protein formats used in sports and clinical nutrition.

Ingredion and Lantmännen formalized their pea-protein partnership in November 2024. Lantmännen committed more than €100 million to a Swedish facility intended to produce yellow-pea protein isolates, with completion expected in 2027. The investment links regional crop supply with ingredient application and commercialization expertise.

Fonterra advanced its portfolio transformation in 2025. The company agreed to sell its global Consumer businesses to Lactalis for NZUSD 4.22 billion and continued work on functional-protein capacity at Studholme. Both moves reinforce its focus on higher-value B2B dairy ingredients.

Roquette expanded the NUTRALYS® range between 2024 and 2026. The company launched NUTRALYS® Fava S900M in May 2024, NUTRALYS® T WHEAT 600L and T PEA 700XC in June 2025, and NUTRALYS® Pea 850F in February 2026.

The insect-protein sector underwent further restructuring in 2025. Ÿnsect ceased operations in December 2025, and Innovafeed suspended operations at its Decatur facility, underscoring the gap between pilot-scale investment and competitive production economics.

Bunge acquired IFF's soy protein operations in August 2025. Bunge agreed to acquire IFF's soy protein concentrate, lecithin, and soy crush operations generating approximately USD 240 million in 2024 revenue, allowing IFF to focus on higher-margin isolated soy protein activities.